153 related articles for article (PubMed ID: 7646611)
1. In-vitro and in-vivo activity of DWC-751, a new cephalosporin.
Choi KH; Kim DJ; Shim JS; Choi MJ; Park NJ; Kim BO; Yu YH; Choi EC
J Antimicrob Chemother; 1994 Jun; 33(6):1233-7. PubMed ID: 7646611
[No Abstract] [Full Text] [Related]
2. [New cephalosporins].
Olarte-Luis T; Cáceres-Galíndez D; Cortés JA
Rev Chilena Infectol; 2018; 35(5):465-475. PubMed ID: 30724992
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
4. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
Acred P; Ryan DM; Sowa MA; Watts CM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
[TBL] [Abstract][Full Text] [Related]
5. Endophthalmitis: antibacterial activity of precipitates of vancomycin and ceftazidime.
Chen KJ; Chen TL; Lai CC; Sun MH
J Clin Microbiol; 2008 Jun; 46(6):2149. PubMed ID: 18539703
[No Abstract] [Full Text] [Related]
6. Biological activity of BO-1236, a new antipseudomonal cephalosporin.
Nakagawa S; Sanada M; Matsuda K; Hazumi N; Tanaka N
Antimicrob Agents Chemother; 1987 Jul; 31(7):1100-5. PubMed ID: 3116919
[TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC
J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
[TBL] [Abstract][Full Text] [Related]
10. Re: Acute bacterial prostatitis in Korea.
Etienne M; Caron F
Int J Antimicrob Agents; 2009 Aug; 34(2):185-6. PubMed ID: 19342203
[No Abstract] [Full Text] [Related]
11. Frequently isolated bacteria and their culture and sensitivity pattern in a medical ICU.
Butt T
J Coll Physicians Surg Pak; 2014 Jul; 24(7):533-4. PubMed ID: 25052984
[No Abstract] [Full Text] [Related]
12. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
13. Comparison between the efficacy of cefotaxime and cephalothin on several infections by gram (+) and gram(-) bacteria.
Huerta MD; Valenzuela F
Proc West Pharmacol Soc; 1991; 34():373-8. PubMed ID: 1788318
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
[TBL] [Abstract][Full Text] [Related]
15. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
Gimeno C; Borja J; Navarro D; Valdés L; García-Barbal J; García-de-Lomas J
Chemotherapy; 1998; 44(2):94-8. PubMed ID: 9551238
[TBL] [Abstract][Full Text] [Related]
16. The postantibiotic effect (PAE) of the new penem FCE 22101 on gram-positive and -negative bacteria in vitro and in vivo.
Bergholm AM; Dornbusch K
J Chemother; 1989 Jul; 1(4 Suppl):64-6. PubMed ID: 16312306
[No Abstract] [Full Text] [Related]
17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftazidime, cefotaxime and gentamicin against 11,521 clinical isolates of bacteria.
Steinbakk M; Midtvedt T; Lingaas E; Gardsjord G
Acta Pathol Microbiol Immunol Scand B; 1987 Dec; 95(6):337-46. PubMed ID: 3326398
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
[TBL] [Abstract][Full Text] [Related]
20. Trends in paediatric and adult bloodstream infections at a Ghanaian referral hospital: a retrospective study.
Obeng-Nkrumah N; Labi AK; Addison NO; Labi JE; Awuah-Mensah G
Ann Clin Microbiol Antimicrob; 2016 Aug; 15(1):49. PubMed ID: 27539221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
